Gara Jalqabaatti › Dukkana Dhiigaa › North Carolina
Qorannoo klinikaalii Dukkana Dhiigaa North Carolina keessatti
Qorannoo 24 Dukkana Dhiigaa f North Carolina keessatti hirmaatuu jiru.
Magaalota North Carolina keessatti
Takkalaa qorannoo (Ingiliffa)
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Duke Cancer Center Cary, Cary
- Duke University Medical Center, Durham
- East Carolina University, Greenville
- fi 4 dabalataa
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT04242095Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- WakeMed Cancer Care - Waverly Hematology & Medical Oncology ( Site 0074), Cary
- University of North Carolina at Chapel Hill ( Site 0040), Chapel Hill
- Duke Cancer Center ( Site 0028), Durham
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- fi 6 dabalataa
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 40 hanga 75 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT05334069Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 27, Chapel Hill
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 71 · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT07504458Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT07648264Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- UNC School of Medicine, Division of Hematology, Chapel Hill
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT04588922A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Novant Health Weisiger Cancer Institute, Charlotte
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 0 fi ol · Saalaa hunda · Haaromfame 02-Ful-2026 · NCT07154823Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of North Carolina, Chapel Hill, Chapel Hill
- Duke University Medical Center, Durham
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Atrium Health Levine Cancer Center, Charlotte
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT06001788DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill
Namoota walitti qabaa jira
Umuriin 60 fi ol · Saalaa hunda · Haaromfame 14-Hag-2026 · NCT06296368A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Levine Cancer Institute, Charlotte
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Hag-2026 · NCT06823167PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- Lineberger Cancer, Chapel Hill
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT06665100ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
- Levine Cancer Insitute, Charlotte
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ado-2026 · NCT07203534Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment
- 2400 Pratt Street, Durham
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 08-Ado-2026 · NCT06532773Implementation of an Oral Chemotherapy Adherence Intervention
- UNC Chapel Hill, Chapel Hill
Namoota walitti qabaa jira
Umuriin 21 fi ol · Saalaa hunda · Haaromfame 08-Ado-2026 · NCT06989489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of North Carolina at Chapel Hill, Chapel Hill
- Levine Children's Hospital, Charlotte
- Duke University Medical Center, Durham
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 06-Ado-2026 · NCT01351545Optimizing Health Related Quality of Life Measurement in Adolescent and Young Adult Oncology
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 15 fi ol · Saalaa hunda · Haaromfame 30-Wax-2026 · NCT06897137Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of North Carolina, Chapel Hill
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 13 fi ol · Saalaa hunda · Haaromfame 05-Cam-2026 · NCT04771572CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Duke University Medical Center, Duke Cancer Center, Durham
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Elb-2026 · NCT03328078A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Duke Blood Cancer Center, Durham
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT05735184HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
- Duke University Health System, Durham
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ama-2026 · NCT06731504A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
- Levine Cancer Institute, Charlotte
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Wax-2025 · NCT05768269IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Atrium Health Wake Forest Baptist, Winston-Salem
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Wax-2025 · NCT06119685Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Carolina-Levine Children's Hospital, Charlotte
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 1 hanga 21 · Saalaa hunda · Haaromfame 06-Mud-2024 · NCT05476770Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.